Skip to main content
Sign In
 

Rheumatoid Arthritis Research Studies


The Division of Rheumatology strives to understand more about rheumatoid arthritis (RA) through research.  Please see the list below, which summarizes the studies available to individuals interested in advancing our understanding and treatment of rheumatic disease. 
 
​Study Name Brief Description​ Basic Eligibility​ Criteria Contact​
​AMP Synovial Biopsy ​Biopsy of joint tissue using ultrasound Early ​RA and patients transitioning between therapies due to poor response ​303-724-0581 or email karen.franklin@ucdenver.edu
​StopRA ​Use of an approved medication (hydroxychloroquine) to prevent or stop the development of RA.  This study includes a placebo group. Individuals with a ​positive blood test (anti-CCP antibody) or their close relatives (parents, siblings, children) ​(303) 724-8330 or email StopRA@UCDenver.edu or www.stop-ra.org
abatacept versus adalimumab ​Comparison of two approved medications (abatacept & adalimumab).  This study does not include a placebo group. ​All individuals must be positive for both RA blood tests (anti-CCP and RF), with symptoms of less than 12 months, and naive to biologic therapies.  ​303-724-0581 or email karen.franklin@ucdenver.edu
 
Please note that study status changes frequently and therefore, a listed study may not be actively enrolling. Also, the complete list of inclusion and exclusion criteria for a given study is often not listed due to its length.  A visit to determine an individuals eligibility may be required.  A placebo is an inactive substance or treatment that looks the same as, and is given the same way as, an active drug or treatment being tested. The effects of the active drug or treatment are compared to the effects of the placebo.